ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc (ATNM)

1.875
0.095
( 5.34% )
Updated: 15:20:04

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.875
Bid
-
Ask
-
Volume
197,954
1.82 Day's Range 1.915
1.33 52 Week Range 10.24
Market Cap
Previous Close
1.78
Open
1.87
Last Trade
1
@
1.875
Last Trade Time
15:22:28
Financial Volume
$ 371,866
VWAP
1.8785
Average Volume (3m)
858,776
Shares Outstanding
31,154,376
Dividend Yield
-
PE Ratio
-1.20
Earnings Per Share (EPS)
-1.57
Revenue
81k
Net Profit
-48.82M

About Actinium Pharmaceuticals Inc

Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and re... Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ('r/r AML'), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ('NCI') under the Cooperative Research and Development Agreement ('CRADA') for development of Actimab-A in AML and other myeloid malignancies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Actinium Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker ATNM. The last closing price for Actinium Pharmaceuticals was $1.78. Over the last year, Actinium Pharmaceuticals shares have traded in a share price range of $ 1.33 to $ 10.24.

Actinium Pharmaceuticals currently has 31,154,376 shares outstanding. The market capitalization of Actinium Pharmaceuticals is $55.45 million. Actinium Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.20.

ATNM Latest News

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. PR Newswire NEW YORK, Aug. 5, 2024 FDA determined that the Phase 3 SIERRA trial is not adequate...

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications PR...

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University PR...

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US PR Newswire NEW YORK, July 25, 2024 Presentation to highlight positive outcomes of Iomab-B led bone...

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid...

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial PR Newswire NEW YORK, June...

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting PR Newswire NEW...

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.095-4.822335025381.972.011.752886631.83795387CS
4-0.255-11.97183098592.132.151.683572461.89731866CS
12-5.535-74.69635627537.418.641.338587763.03665309CS
26-5.725-75.32894736847.610.241.335897074.89551211CS
52-4.375-706.2510.241.333913125.08811438CS
156-5.625-757.515.121.333523837.22191393CS
2601.6451715.5719878210.229915.120.150618026991.52393698CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SGNSigning Day Sports Inc
$ 0.517
(298.00%)
532.03M
ATCHAtlasClear Holdings Inc
$ 0.1716
(20.51%)
1.02M
MSTUT Rex 2X Long MSTR Daily Target ETF
$ 30.55
(19.72%)
1.13M
RYDERyde Group Ltd
$ 1.29
(14.16%)
7.85M
ETHTProshares Ultra Ether ETF
$ 13.65
(13.66%)
240.27k
MSTZT Rex 2X Inverse MSTR Daily Target ETF
$ 19.8267
(-18.92%)
28.05k
EFSH1847 Holdings LLC
$ 1.7001
(-15.00%)
141.83k
HCWCHealthy Choice Wellness Corp
$ 2.99
(-14.57%)
213k
ETHDProshares Ultrashort Ether ETF
$ 63.50
(-13.88%)
33.42k
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 21.7699
(-12.64%)
80.13M
SGNSigning Day Sports Inc
$ 0.517
(298.00%)
532.03M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 35.095
(12.70%)
102.15M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 21.7699
(-12.64%)
80.13M
SPYSPDR S&P 500
$ 571.43
(1.79%)
48.46M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
$ 6.8397
(-5.40%)
46.52M

ATNM Discussion

View Posts
timberwolf7 timberwolf7 4 days ago
Last I UNDERSTAND on ATNM is that the fed death agency is going to require a NEW PH 3. Means this one is pretty much 'dead' for the next year minimum since they don't
have anything else in the pipeline. And at some point, having to see more shares to raise cash.

What a screw job the fda pulled on them based on what the company has said so far.
๐Ÿ‘๏ธ0
grubstake grubstake 4 days ago
Thanks Timber (I think you dropped CRMD here too, my brother has some, that oneโ€™s moving of late.)Yes once ICU gets approval for ADULT akiโ€ฆ much bigger population. I remember them alluding to potential use for organ transplant treatment in future, and many other paths. Just looked up Ihub ICU board: https://investorshub.advfn.com/SeaStar-Medical-Holding-Corp-ICU-42335
Now back to our ATNM waiting for some good newsโ€ฆ that brings us back to $6 then $10โ€ฆ :c
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 6 days ago
On ICU... only 4 or so Mil shares, thats nice to see (course they did a r/split to get there)

Bigger issue may be the SMALL population of potential patients in terms of who THEY see
as their potential 'market'..

Interesting 'development', something I am familiar with in terms of it basically being a
blood 'conditioner'. Got to look into how well it really works from the aspect of, if someone
gets this 'condition', will the facility see their development as something they HAVE to try.

On NSPR, I don't own any yet. Still watching the momentum which is weighing negative,
but the share price is resisting breaking down, holding $2.7. Was hoping it would drop to $2.50
or less...But will be getting some before their next earnings call just in case they say something along
the lines of revenues/sales in the overseas markets continues to move higher..
👍️ 1
grubstake grubstake 7 days ago
I learned of nspr from you here, it was a buck and I missed it as it went through $2, I hold some now but at par. Shoulda listened at $1! ICU is unique though (not ICUI) with apparent blue skies on many fronts, time factor and burn rate holding them back. https://journey.ct.events/view/7f792b7c-2391-4da5-9718-55622babdcae thanks for replyโ€ฆ
not for the faint of heart!
👍️ 1
timberwolf7 timberwolf7 7 days ago
Oops, wrong company.. Meant AWE platform for attacking solid tumors...

If you are looking at something to get into, check out NSPR.. They have just submitted an application for approval for a
stent design that IS a lot better than the current technology being used. They are anticipating a decision in the 1st half of 2025.
I have traded the shares a couple of times in the past, have a 'very conservative' initial target price of $5. Which from the current
price of around $2.75, would be around a 80% POTENTIAL return IF the fda approves their medical DEVICE (not a drug). Which
is already approved overseas and is being sold/used. (but no secret, you want to generate serious revenues, you need to be approved
to sell into the US market).
Disclaimer: I don't own any at the moment, just watching to see if the share price will keep slipping off its recent highs from the news
that they submitted their application.
NOTE; will check into ICU, but from an initial quick look at what they are doing, I prefer to find companies that are doing something much better
than whats already on the market, or something NEW... AKA, ATNMs conditioner effort and still can't believe what happened to them.

https://www.actiniumpharma.com/awe-technology

Actinium's Antibody Warhead Enabling (AWE) Technology Platform
Actinium's AWE technology platform is used to produce ARCs or Antibody Radiation Conjugates, a highly potent and selective form of targeted radiotherapy. ARCs enable the precision targeting of the proven therapeutic power of radiation to tumors and its synergistic potential with other therapeutic modalities that cannot be matched by traditional external beam radiation, cytotoxic chemotherapy or biologic therapies. AWE enabled ARCs exploit the use of highly selective targeted biological agents such as monoclonal antibodies that can seek out and bind cancer antigens found on the tumor cell surface to deliver potent radioisotopes that are capable of producing double strand DNA breaks for which there is no known resistance or repair mechanisms.
👍️ 2
grubstake grubstake 1 week ago
Timber please, what is WAR programs?โ€ฆ
I tried to get a comment from ATNM investor relations on situation but no response.
also, have you looked into ICU stock? thanks
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 1 month ago
On a possible buyout. Yep, this screw job by the fda could be part of something
to corner ATNM management into doing something they weren't prepared to do.

The other question I hadn't really spent much time on yet is, just how good is their
WAR programs? How good/effective is the technology.

.
๐Ÿ‘๏ธ0
Stantheplan Stantheplan 1 month ago
With the recent price drop the majority shareholders in ATNM may be softened up enough to accept a much lower buyout price for the company but the question is will Seth be willing to sell. If he does it will be before Thanksgiving of this year imo.
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 1 month ago
Worst part is, their development appears to actually HELP people

So why in the hell would the fda say, redo the trial vs
do a PH 4 follow up trial following approval.

Unfricking real..
👍️ 1
timberwolf7 timberwolf7 1 month ago
Yeah, I sold out some years ago as well, held off taking a new position until recently.

Got a 1000 shares at $7.55, have $900 in profits off the covered calls. So going to keep doing that
while this gets figured out. Only concern is whats going to happen to the value of the calls as this
quiets down.. Might be tough to get a lot for them.

Yep, have seen enough out of the fda to again, realize its integrity has been compromised.. And that
IS NOT a good thing..

But sadly, its just a reflection of the overall breakdown in morals, ethics, integrity, honesty in this world now.
Replaced by the desire for GREED and POWER no matter what gets sacrificed to get it.
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 1 month ago
Thank you for your reply which confirms my feelings regarding FDAโ€™s lack of integrity surrounding the approval process. Iโ€™m happy that I sold about half of my position a couple of years ago (at around 12). I guess we wait for an unsatisfying buyout?
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 1 month ago
Yep, thats my understanding as well. They concurred in the trial, which means they
had agreed on the 'acceptance' criteria.

But at least this explains WHY its taken them so long to announce filing for approval.

And been a long time observer/concluder that the FDA doesn't have the publics best
interest as their primary goal. Figured it out some years ago that big pharma runs the
fda, guides its 'decisions'.

Even to the point where I have suspected that new ideas trying that are 'targets' by
a big pharma who would like to own the idea, may find it harder to get to their end point.
To the point they become illiquid and forced to 'negotiate' just so that the developers can
get something for their efforts.

Or even worse, in this case, since this does appear to HELP people going thru treatment,
that despite this conclusion, the fda doesn't give a damn that it does. And once again, instead
of saying, we will approve but you have to do a PH 4 followup to conclude just how well it works.
We are going to flat out DENY the ones that could benefit from this from using it to help extend/save
their lives. Nope, we are going to endanger lives instead by DENYING them a potential treatment
that has shown it can help them. That to me is the really sick part of this mess.

Yep, sure appears to be a royal screw job. Not just for ATNM, but really for those that it could HELP.
👍️ 1
Pharmboy46 Pharmboy46 1 month ago
I believe it was Astra Zenica buying Force Pharmaceuticals?
๐Ÿ‘๏ธ0
grubstake grubstake 1 month ago
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
Can they get approval outside the US?
๐Ÿ‘๏ธ0
grubstake grubstake 1 month ago
Perhaps a new partner is on the bidโ€ฆ?
With deep pocketsโ€ฆ
Did the drug makers pressure fda to force this?
๐Ÿ‘๏ธ0
north40000 north40000 1 month ago
Did some company like ABBV or ABT or GSK buy that other Actinium using company?
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 1 month ago
There are other companies that use the radio therapeutic actinium investigationally. FDA has approved its use in clinical trials to treat prostate, breast and other solid tissue cancers, but, I couldnโ€™t find any information on any company that holds marketing approval.
๐Ÿ‘๏ธ0
north40000 north40000 1 month ago
Didnโ€™t FDA just approve another companyโ€™s drug that also contained actinium?
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 1 month ago
I think they are mostly big pharma- centered. The deck is truly stacked against the smaller players. Itโ€™s a shame because most of the true innovation comes from the small guys!
๐Ÿ‘๏ธ0
Zadie420 Zadie420 1 month ago
FDA is a criminal agency. How could exert a pressure on patients not to cross over when it comes to life and death. FDA needs to use ECA and other documented data to compare and evaluate the results.
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 1 month ago
The message from the company is that they have to run a whole new trial (apparently without a cross over option)
๐Ÿ‘๏ธ0
Zadie420 Zadie420 1 month ago
Now what kind of test they want to run? Is it full trial size or what?
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 1 month ago
Wow. The FDA really screwed us on this one. One must question if the FDA really has the publicโ€™s interest in mind when making these decisions. If Iโ€™m understanding it correctly, FDA approved the SIERRA study, even went so far as to say that it would be enough to garner approval, then decided that it wasnโ€™t enough to file a BLA?
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 1 month ago
fda just screwed ATNM over by telling them the trials acceptance criteria (which the FDA 'accepted' when the trial was
put together) needs to be changed.

https://ir.actiniumpharma.com/press-releases/detail/486
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 2 months ago
Would like to see them get their NDA submitted already.

Be nice to see them advancing their first product to market to start generating

some revenues.

For everything else they are 'spending' cash on is years from generating revenue unless

its good enough for them to be bought out or gain a partnership.
๐Ÿ‘๏ธ0
grubstake grubstake 2 months ago
Todayโ€™s news was interesting in that atnm Will start on path developing new method to treat sickle cell cases. This will have the attention of.Vertex as an alternative to chemo. VRTX is working with CRSP on their first approved treatment using CRSPR TECHNOLOGY for sickle disease . It would be quite nice for.ATNM to rub shoulders withVRTX and CRSP as they have very deep pockets! Might pull in those calls LOL
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 2 months ago
LOL...

Nope, been a while since I was serious about holding shares for the NDA submission.

But noticed the calls have some 'value' to them, and also that accumulation occurred in

APRIL, MAY and its happening again now. (have a sentiment indicator I monitor on the

charting software I use)..

Should actually send a message to their IR and ask them to update folks on their

NDA submission status. Like what in the heck is taking so long (smile)
๐Ÿ‘๏ธ0
oldstocks oldstocks 2 months ago
Not much posting here, so you are the one buying all the shares to take it to $10?

Thank you

No really it is moving up nicely
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 2 months ago
Started my accumulation of shares this morn.

But also selling covered calls on the shares while I wait.

Got shares at $7.55 and sold the Sept $10 Strike price for .55 cents/..

good way to get some gains, hopefully hold onto the shares in the process.

Good luck.
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 3 months ago
Oddly 5400 volume after hours.
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 3 months ago
Something is up with this one.
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 3 months ago
The time to be in is right before close on Friday. News could be over the weekend and Monday morning nice gap and run.
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 3 months ago
ATNM with BLA news, should realistically hit 30 dollars minimum in multiple days.
🤥 1
dinogreeves dinogreeves 3 months ago
Way too much manipulation on level 2, been watching the trades for the past 2 weeks, that is why I got in yesterday.
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 3 months ago
Who knows BLA is suppose to be this month, not holding my breath though. Either this month or sometime in after July 4th. What I am seeing is people getting in for news everyday and when news doesn't come they sell the next day.
🕳️ 1 🪦 1 ☠️ 1 ⚰️ 1
timberwolf7 timberwolf7 3 months ago
I don't own any at the moment. Been a while actually since I have held any position for that matter

That said, with the announcement of the filing of the NDA anticipated sometime between the end of
June and December??

Been thinking of 'playing' the announcement. But at the moment, ATNM is in a confirmed
downtrend. So going to be patient to see what this gets down to first..

Do like the Nov %5s for $3.20/ 2x as many vs the shares and only a $ in 'premium'.

But again, see how low this goes first..

Good luck
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 3 months ago
Bought 90 calls all the way out to November in the money, also bought 1500 shares at the end of day.
🤥 1
timberwolf7 timberwolf7 3 months ago
popping on the news of a PH 1 trial.. so they buying to take what

the news 'gives' this morn or are they buying to hold the shares for

the next 2 - 2+ years till the PH 2 is over and reads out

Just read their MAY 2024 presentation and see they are now

targeting the 2nd HALF of 2024 for an NDA on IO-B.. taking a

long time to get this NDA submitted, and then take on another 9

months for a decision. Mercy...

IE, don't expect the share price to do much until they announce the NDA submission now,

and then it will be up to the PH 2s on the ARC developments to give us insights into what its

potential really is..

Good luck
๐Ÿ‘๏ธ0
north40000 north40000 3 months ago
Maybe soon. ATNM trading at $8.40 this morning, pre-market opening, +7.42%.
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 5 months ago
Good luck. Somethingโ€™s gotta give soon! Iโ€™d love to see that 25 dollar mark before the end of the year.
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 5 months ago
Back in with the first buy in a long time... Still have a target price of $25.. Ticked that CRMD has taken so long to get going cause it made me miss one heck of a buying opp on ATNM sub $5...

Now to start selling covered calls and see if I can keep the shares..


Good luck..
๐Ÿ‘๏ธ0
Monroe1 Monroe1 6 months ago
The troll idiot rides again making up lies when his ass gets burned.

LMAO, what a piece of work.
๐Ÿ‘๏ธ0
fung_derf fung_derf 6 months ago
LOL!! Is this your "timing" post?? Yes, you only made it 8 years ago....great timing....of course the stock was around $62 then

Monroe1

Re: None

Tuesday, September 27, 2016 10:17:02 AM

Post#
1092
of 2790
So what is the ETA for lomab coming out of phase3 and approval?
Mid 2017 or earlier perhaps??
๐Ÿ‘๏ธ0
north40000 north40000 6 months ago
Suppose that PT is raised in light of AZN buying Fusion at ~ 100% premium today? Much needed Actinium involved there also
๐Ÿ‘๏ธ0
oldstocks oldstocks 6 months ago
Maxim Group Maintains Buy on Actinium
Pharma, Raises Price Target to $30
3/19/2024 12:59pm
12:59 PM EDT, March 19, 2024 (Benzinga Newswire)
Maxim Group analyst Jason McCarthy maintains
Actinium Pharma (AMEX:ATNM) with a Buy and raises the price target from $20 to $30.
Write to Benzinga at editorial@benzinga.com
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 6 months ago
I continue to believe that potential suitors are waiting for ATNM to, at the very least, submit their application to the FDA. Possibly the company even had some offers but would be in a better position to negotiate after approval?
๐Ÿ‘๏ธ0
oldstocks oldstocks 6 months ago
Watching Actinium Pharmaceuticals; HC
Wainwright: First Take Says 'Appetite Remains High For Radiopharmaceuticals;
We See Actinium As Ripe For Takeout And Believes It Is Receiving M&A Interest'
3/19/2024 11:24am
๐Ÿ‘๏ธ0
oldstocks oldstocks 6 months ago
HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price Target
3/19/2024 11:19am
11:19 AM EDT, March 19, 2024 (Benzinga Newswire)
HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price target.
Write to Benzinga at editorial@benzinga.com
๐Ÿ‘๏ธ0
Pharmboy46 Pharmboy46 6 months ago
Good news but we can sure use that FDA submission.
๐Ÿ‘๏ธ0
oldstocks oldstocks 6 months ago
Actinium Pharmaceuticals Disclosed The Launch Of Strategic Initiative Focused On The Manufacture Of The Highly Sought After Medical Isotope Actinium-225 (Ac-225)
3/14/2024 6:11am
👍️ 1

Your Recent History

Delayed Upgrade Clock